Myasthenia Gravis
Myasthenia gravis is an autoimmune disorder affecting the myoneural junction which is a synapse formed between motor neuron and a muscle fiber. MG is characterized by varying degrees of weakness of the voluntary muscles.
In MG, the receptors at the muscle surface are destroyed or deformed by antibodies that prevent a normal muscular reaction from occurring.
The causative factor is unknown, but the disorder may have a genetic link. The risk factors may include presence of other autoimmune disorders, presence of thymoma which is a rare, usually benign tumor arising from thymus tissue. MG occurs at any age and in any race. The incidence is approximately
9 to 21 cases per million persons. MG is most common in women, incidence in females peaks at ages 30 to 39 and in males at ages 60 or older.
Please watch the video provided in the hyperlink about some key points to understand Myasthenia gravis.
Factors that can worsen myasthenia gravis symptoms are Fatigue
Illness/infection
Stress/emotional distress
Extreme heat
Some medications — such as beta blockers, calcium channel blockers, quinine and some antibiotics such as Fluoroquinolones and aminoglycosides can make MG symptoms worse.
The clinical manifestations of Myasthenia gravis include Diplopia (double vision) and Ptosis which is drooping of the eye lid. Weakness of the muscles of the face and the throat, and generalized weakness. Patient experience extreme muscle weakness and fatigue especially at the end of the day. Weakness of the facial muscles results in bland facial expression. Laryngeal irritation causes voice impairment and dysphonias and increases the patient’s risk for choking and aspiration. Generalized weakness of all the extremities and the intercoastal muscles results in decreased respiratory capacity. Myasthenia gravis is purely a motor disorder with no effect on the sensation and coordination.
The complications of MG involve
Respiratory Distress
Acute Respiratory failure
Atelectasis
Pneumonia
Dysphagia
Aspiration
Myasthenic Crisis which is exacerbation of MG requiring mechanical ventilation related to weakness of the respiratory muscles.
Cholinergic Crisis causing neuromuscular weakness and respiratory failure related to use of high-dose cholinesterase inhibitors
The diagnostic studies for MG involve complete history and physical.
Edrophonium also called Tensilon Test is used for diagnostic purposes.
IV Injection of the chemical edrophonium (Tensilon) may result in a sudden, although temporary, improvement in muscle strength - an indication that patient may have myasthenia gravis.
Tensilon is an anticholinesterase agent and it temporarily shows improved muscle contractility . It Inhibits destruction of acetylcholine by cholinesterase and facilitates transmission of impulses across myoneural junction. Tensilon does not improve muscle weakness but it can make it worse, therefore Atropine which is an antidote to Tensilon should be readily available to counteract its effects.
Presence of abnormal antibodies that disrupt the receptor sites where nerve impulses signal muscles to move can help in diagnosis of MG.
Cooling may improve neuromuscular transmission. Ice pack test result for the patients whom Tensilon test is contraindicated reveal decreased ptosis after application of ice for 60 seconds to the closed eyelid.
CT scan for thymus will show presence of thymoma.
The treatment of MG includes use of Anticholinesterase agents such as pyridostigmine and neostigmine. Pyridostigmine ( Mestinon) is the most successful drug for long term treatment of MG. Cholinesterase inhibitors enhance function of neuromuscular junction by inhibiting acetylcholinesterase enzyme which breaks down acetylcholine .It helps in prolonging the action of Acetylcholine and facilitate transmission of impulses.
Corticosteroids such as Prednisone and Immunosuppressants such as Imuran, Cyclosporine (Sandimmune), mycophenolate (cellcept) are used in treatment of MG.
Plasmapheresis is also an option for treatment of MG for the exchange of plasma to remove antibodies.
IVIG treatment requires close monitoring for any possible reactions.
Patients may require surgical intervention called thymectomy to remove the thymus gland to control symptoms of MG.
The nursing assessment for MG involves assessment for the severity of the symptoms, respiratory effort including rate and depth of respirations, oxygen saturation, ABGs and PFT . Assessing muscle strength of face and limbs and assessment of swallowing, speech , cough and gag reflexes. Assess patient’s coping abilities so that appropriate resources can be provided.
The main goal of treatment for MG patients is the return of normal muscle endurance, being able to manage fatigue, avoid complications and
maintain a quality of life appropriate to the disease process.
One of the priority intervention of nursing management for MG is maintaining adequate ventilation. Ensure patent airway and monitor for myasthenic crisis for increased respiratory distress and failure. Make sure that emergency respiratory equipment is readily available at the bed side. If assisting with diagnostic testing, monitor for adverse effects of Tensilon testing. Monitor for side effects of drug therapy. Know the difference and onset of manifestations of myasthenic crisis and cholinergic crisis.
Myasthenic crisis is the exacerbation of MG symptoms following precipitating factors or failure to take medications. The patients will have improved strength after IV administration of anticholinergic drugs.
However, Cholinergic Crisis occurs after overdose of anticholinesterase drugs resulting in excess accumulation of Acetylcholine at receptor sites of neuromuscular junction. The muscles stop responding to overdose of Acetylcholine and results in increased weakness within 1 hour of taking the dose. The patients will require to be withdrawn from anticholinesterase medication, mechanical ventilation if respiratory symptoms are severe and administration of Atropine.
Educate patient on balanced diet with nutrient dense foods. Encourage patient to chew slowly and note any changes in the ability to chew. Encourage the use of thickened liquids, semi solid diet that is easy to be chewed and swallowed if patient has difficulty swallowing.
Appropriate scheduling of medications is critical so that the peak time for the medication is at the at mealtime. Pyridostigmine(Mestinon)should be scheduled 45 to 60 minutes before meal time and should be given with a small amount of food to prevent GI upset, but the patient should wait 45 to 60 minutes to eat a full meal due to the potential for aspiration. If difficulty with swallowing occurs, then patient should seek immediate attention. Mestinon dose can change on a day-to-day basis depending on manifestations of the disease.
Encourage patient to do physical demanding activities early in the day as muscles are generally strongest in the morning. Educate patient on the importance of compliance with medication regimen.
The patient should be made aware of the complications of therapy such as cholinergic crisis. Provide community resources such as Myasthenia Gravis Associations and MG support groups.








